First Manhattan’s Aquestive Therapeutics AQST Stock Holding History

First Manhattan’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$902	–	1533
2022 Q4	$902	Hold	1,000	–	–	﹤0.01%	1588
2022 Q3	$1K	Sell	1,000 -1,000	-50%	-$1.13K	﹤0.01%	1451
2022 Q2	$1K	Hold	2,000	–	–	﹤0.01%	1464
2022 Q1	$5K	Hold	2,000	–	–	﹤0.01%	1373
2021 Q4	$7K	Hold	2,000	–	–	﹤0.01%	1322
2021 Q3	$8K	Sell	2,000 -600	-23%	-$2.35K	﹤0.01%	1318
2021 Q2	$10K	Buy	+2,600	New	+$10.4K	﹤0.01%	1271
2020 Q4	–	Sell	-600	Closed	-$2K	–	1328
2020 Q3	$2K	Buy	600 +300	+100%	+$1.96K	﹤0.01%	1262
2020 Q2	$1K	Buy	+300	New	+$1.38K	﹤0.01%	1339

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAFP

Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

First Manhattan's AQST Position: Q1 2023 in Review

First Manhattan sold out of Aquestive Therapeutics (AQST) in Q1 2023, closing a stake of 1,000 shares — an estimated $902 sold.

First Manhattan first reported a position in AQST in Q2 2020 and held it in 9 quarters. The position peaked at $10K in Q2 2021. 35 funds tracked by Wall St. Rank hold AQST as of Q1 2023.

First Manhattan reported no remaining Aquestive Therapeutics position as of Q1 2023 after selling out during the quarter.
First Manhattan sold 1,000 Aquestive Therapeutics shares in Q1 2023, an estimated $902.
First Manhattan first reported a position in Aquestive Therapeutics in Q2 2020 and held it in 9 quarters.
First Manhattan's Aquestive Therapeutics position peaked at $10K in Q2 2021.
35 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2023.

Based on First Manhattan's 13F filing for Q1 2023, filed 15 May 2023.